利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.04 秒)

    High temperature carbonaceous cement
    21.
    发明授权
    High temperature carbonaceous cement 失效

    公开(公告)号：US06214158B1

    公开(公告)日：2001-04-10

    申请号：US09258517

    申请日：1999-02-26

    申请人： Charles Chi-Chieh Chiu ,  Irwin Charles Lewis ,  Richard Thomas Lewis

    发明人： Charles Chi-Chieh Chiu ,  Irwin Charles Lewis ,  Richard Thomas Lewis

    IPC分类号： C09J504

    CPC分类号： C04B26/10 ,  C04B14/022 ,  C04B35/632 ,  C04B35/645 ,  C04B37/008 ,  C04B41/5001 ,  C04B2235/6562 ,  C04B2235/6567 ,  C04B2237/086 ,  C04B2237/09 ,  C04B2237/363 ,  C04B2237/52 ,  C04B2237/708 ,  C04B2237/72 ,  C08G73/101 ,  C08L75/02 ,  C09J5/02 ,  C09J5/06 ,  C09J2475/00

    摘要： A curable, high temperature, carbonaceous, cement paste composition comprising a catalyst; a carbon filler present in an amount of about 20 to about 60 wt. %; a polymerizable monomeric system present in an amount of about 7 to about 30 wt. % comprising a dialkyl ester of an aromatic tetracarboxylic acid, an aromatic diamine, and a monoalkyl ester of an acid selected from the group consisting of 5-norbornene-2,3-dicarboxylic acid and phthalic acid; and a furan solvent present in an amount of about 20 to about 60 wt. %. The most preferred embodiment comprising a monomeric system comprising a dimethyl ester of 3,3′,4,4′-benzophenonetetracarboxylic acid, 2,2′-bis (4-[4-aminophenoxyl]phenyl)propane and a monomethyl ester of 5-norbornene-2,3-dicarboxylic acid with furfuryl alcohol and a catalytic solution of about 50% ZnCl2, has a glass transition temperature of about 280° C. after curing by heating at about 2° C./minute to about 240° C. and holding for about 2 hours. Upon curing, the cement paste composition maintains a strength of at least about 2000 psi at room temperature after heat treatment at about 3000° C. even when cured at a substantially lower temperature of at least about 200° C. Subsequent heating of the monomeric binder causes further cross-linking producing a stronger and more stable cement for use at service temperatures greater than the initial glass transition temperature of the cured cement. The curable cement composition may be used along with a pre-coat in an adhesive system for attaching together carbon bodies. Most preferably, the pre-coat comprises about 27 wt. %, of a monomeric system comprising a dimethyl ester of 3,3′,4,4′-benzophenonetetracarboxylic acid, 2,2′-bis (4-[4-aminophenoxyl]phenyl)propane and a monomethyl ester of 5-norbornene-2,3-dicarboxylic acid dissolved in about 65 to about 85 wt. % furfuryl alcohol. A method of making the cement paste composition is also described.

    Aromatic compounds, compositions containing them and their use in therapy
    23.
    发明授权
    Aromatic compounds, compositions containing them and their use in therapy 失效
    芳香族化合物，含有它们的组合物及其在治疗中的应用

    公开(公告)号：US5674889A

    公开(公告)日：1997-10-07

    申请号：US513759

    申请日：1995-08-21

    申请人： Fintan Kelleher ,  Richard Thomas Lewis ,  Angus Murray Macleod

    发明人： Fintan Kelleher ,  Richard Thomas Lewis ,  Angus Murray Macleod

    IPC分类号： C07D209/14 ,  C07D401/12 ,  C07D471/08 ,  A61K31/405 ,  C07D209/10

    CPC分类号： C07D401/12 ,  C07D209/14 ,  C07D471/08

    摘要： The present invention relates to compounds of formula (I) and salts and prodrugs thereof, wherein Q.sup.1 represents a phenyl group substituted by one or more halo optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl or optionally substituted fluorenyl; R.sup.1 represents H or C.sub.1-6 alkyl; R.sup.2 represents H, C.sub.1-6 alkyl or C.sub.2-6 alkenyl; Z.sup.1 represents a group selected from (a) or (b). The compounds are tachykinin antagonists useful for treating pain or inflammation, migraine or emesis.

    摘要翻译： PCT No.PCT / EP94 / 00438 Sec。 371日期1995年8月21日 102（e）日期1995年8月21日PCT 1994年2月15日PCT PCT。 公开号WO94 / 19320 PCT （I）的化合物本发明涉及式（I）的化合物及其盐和前药，其中Q1表示被一个被一个 或更多的卤素任选取代的萘基，任选取代的吲哚基，任选取代的苯硫基苯基，任选取代的苯并呋喃基，任选取代的苄基或任选取代的芴基; R1表示H或C1-6烷基; R 2表示H，C 1-6烷基或C 2-6烯基; Z1表示选自（a）或（b）的基团。 这些化合物是可用于治疗疼痛或炎症，偏头痛或呕吐的速激肽拮抗剂。

    Process of making pins for connecting carbon electrodes
    27.
    发明授权
    Process of making pins for connecting carbon electrodes 有权
    制造用于连接碳电极的引脚的工艺

    公开(公告)号：US06280663B1

    公开(公告)日：2001-08-28

    申请号：US09514219

    申请日：2000-02-25

    申请人： Richard Liichang Shao ,  James William Kortovich ,  Irwin Charles Lewis ,  Richard Thomas Lewis

    发明人： Richard Liichang Shao ,  James William Kortovich ,  Irwin Charles Lewis ,  Richard Thomas Lewis

    IPC分类号： C01B3104

    CPC分类号： C04B35/532 ,  H01M4/583 ,  H01M4/96 ,  Y10T428/249928 ,  Y10T428/30

    摘要： A process for preparing pins for connecting carbon electrodes is presented. In particular, a process for preparing pins for connecting carbon electrodes including the steps of combining calcined coke, a liquid pitch binder and carbon fibers derived from mesophase pitch to form a pinstock blend; extruding the pinstock blend to form a green pinstock; baking the green pinstock to form a carbonized pinstock; and graphitizing the carbonized pinstock by maintaining the carbonized pinstock at a temperature of at least about 2500° C. for no more than about 18 hours is presented. The pins prepared by the inventive process are also presented.

    摘要翻译： 提出了一种制备用于连接碳电极的引脚的工艺。 具体地说，一种制备用于连接碳电极的引脚的方法，包括以下步骤：将煅烧焦炭，液体沥青粘合剂和衍生自中间相间距的碳纤维组合以形成母料共混物; 挤压坯料混合物以形成绿色的坯料; 烘烤绿色的脚骨以形成碳化的脚钉; 并且通过将碳化的母料保持在至少约2500℃的温度下不超过约18小时来呈现碳化的母料的石墨化。 还提出了由本发明方法制备的针。

    Spiro-substituted azacyclic derivatives and their use as therapeutic agents
    28.
    发明授权
    Spiro-substituted azacyclic derivatives and their use as therapeutic agents 失效

    公开(公告)号：US5811431A

    公开(公告)日：1998-09-22

    申请号：US765360

    申请日：1997-01-07

    申请人： Tamara Ladduwahetty ,  Richard Thomas Lewis ,  Angus Murray MacLeod ,  Kevin John Merchant

    发明人： Tamara Ladduwahetty ,  Richard Thomas Lewis ,  Angus Murray MacLeod ,  Kevin John Merchant

    IPC分类号： A61K31/435 ,  A61P1/04 ,  A61P1/08 ,  A61P11/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/28 ,  A61P29/00 ,  A61P37/00 ,  A61P43/00 ,  C07D471/10 ,  A61K31/445 ,  C07D401/04

    CPC分类号： C07D471/10

    摘要： The present invention relates to compounds of formula (I), wherein n is zero, 1, 2 or 3; R represents C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halogen, cyano, trifluoromethyl SO.sub.2 C.sub.1-6 alkyl, NR.sup.a R.sup.b, NR.sup.a COR.sup.b or CONR.sup.a R.sup.b, where R.sup.a and R.sup.b are each H, C.sub.1-4 alkyl, phenyl or trifluoromethyl; R.sup.1 represents phenyl optionally substituted by 1, 2 or 3 of C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, --O(CH.sub.2).sub.p O-- (where p is 1 or 2), halogen, cyano, nitro, trifluoromethyl, trimethylsilyl, OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, NR.sup.a R.sup.b, NR.sup.a COR.sup.b, NR.sup.a CO.sub.2 R.sup.b, COR.sup.a, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b ; naphthyl; benzhydryl; or benyl, where the naphthyl group or each phenyl moiety of benzyl and benzhydryl may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or trifluoromethyl; R.sup.2 represents hydogen, a substituent as defined for R.sup.1 or heteroaryl selected from indazolyl, thienyl, furanyl, pyridyl, thiazolyl, tetrazolyl and quinolinyl; wherein each heteroaryl may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or trifluoromethyl; R.sup.3 and R.sup.4 are each H or C.sub.1-6 alkyl or R.sup.3 and R.sup.4 together are linked so as to form a C.sub.1-3 alkylene chain; R.sup.5 represents H, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenylC.sub.1-4 alkyl, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, SOR.sup.a or SO.sub.2 R.sup.a, wherein the phenyl moiety may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen or trifluoromethyl; X and Y are each H, or together represents .dbd.O; and Z represents a bond, O, S, SO, SO.sub.2, NR.sup.6, or --(CR.sup.6 R.sup.6)-- where R.sup.6 is H or C.sub.1-6 alkyl; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##

    Morpholine derivatives and their use as therapeutic agents
    29.
    发明授权
    Morpholine derivatives and their use as therapeutic agents 失效
    吗啉衍生物及其作为治疗剂的用途

    公开(公告)号：US5719149A

    公开(公告)日：1998-02-17

    申请号：US793573

    申请日：1997-02-27

    申请人： Paul Finke ,  Timothy Harrison ,  Richard Thomas Lewis ,  Angus Murray MacLeod ,  Andrew Pate Owens

    发明人： Paul Finke ,  Timothy Harrison ,  Richard Thomas Lewis ,  Angus Murray MacLeod ,  Andrew Pate Owens

    IPC分类号： A61K31/535 ,  A61K31/5375 ,  A61P1/08 ,  A61P25/04 ,  A61P29/00 ,  A61P43/00 ,  C07D265/32 ,  C07D413/06

    CPC分类号： C07D413/06 ,  C07D265/32

    摘要： The present invention relates to compounds of formula (I) wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are selected from a variety of suitable aromatic substituents; R.sup.6 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, or C.sub.2 -alkyl substituted by C.sub.1-4 alkoxy or hydroxy; R.sup.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, C.sub.2-4 alkyl substituted by C.sub.1-4 alkoxy or hydroxy, or the group C(.dbd.NR.sup.c)NR.sup.a R.sup.b ; or R.sup.6 and R.sup.7, together with the nitrogen atom to which they are attached, form an optionally substituted saturated heterocyclic ring of 4 to 7 ring atoms which may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR.sup.8, S(O) or S(O).sub.2 ; or R.sup.6 and R.sup.7, together with the nitrogen atom to which they are attached, form a piperidino ring substituted by a spiro-fused indene or indoline group, each of which may be unsubstituted or substituted; R.sup.8 is hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl or C.sub.1-4 alkoxyC.sub.1-4 alkyl; R.sup.9a and R.sup.9b are each independently hydrogen or C.sub.1-4 alkyl, or R.sup.9a and R.sup.9b are joined so, together with the carbon atoms to which they are attached, there is formed a C.sub.5-7 ring; X is selected from --CH.sub.2 CH.sub.2 --, --COCH.sub.2 -- or --CH.sub.2 CO--; and Y is hydrogen, or C.sub.1-4 alkyl optionally substituted by a hydroxyl group; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##

    摘要翻译： PCT No.PCT / GB95 / 02039 Sec。 371日期1997年2月27日 102（e）1997年2月27日PCT PCT 1995年8月30日PCT公布。 公开号WO96 / 07649 日期：1996年3月14日本发明涉及式（I）化合物，其中：R 1，R 2，R 3，R 4和R 5选自多种合适的芳族取代基; R 6是氢，C 1-6烷基，C 3-7环烷基，C 3-7环烷基C 1-4烷基，苯基或被C 1-4烷氧基或羟基取代的C 2-烷基; R 7是氢，C 1-6烷基，C 3-7环烷基，C 3-7环烷基C 1-4烷基，苯基，被C 1-4烷氧基或羟基取代的C 2-4烷基或基团C（= NR c）NR a R b; 或R6和R7与它们所连接的氮原子一起形成任选取代的4至7个环原子的饱和杂环，其可以任选地在环中含有一个氧或硫原子或选自NR8，S（ O）或S（O）2; 或R6和R7与它们所连接的氮原子一起形成被螺稠合的茚或二氢吲哚基团取代的哌啶子基环，它们各自可以是未取代的或取代的; R 8是氢，C 1-4烷基，羟基C 1-4烷基或C 1-4烷氧基C 1-4烷基; R9a和R9b各自独立地为氢或C1-4烷基，或者R9a和R9b与它们所连接的碳原子一起连接形成C5-7环; X选自-CH 2 CH 2 - ， - COCH 2 - 或-CH 2 CO-; Y为氢或任选被羟基取代的C 1-4烷基; 或其药学上可接受的盐。 该化合物特别用于治疗或预防疼痛，炎症，偏头痛，呕吐和带状疱疹后神经痛。 （一）